|
Real-time Estimate
Cboe BZX
10:07:30 15/06/2026 pm IST
|
5-day change
|
1st Jan Change
|
|
458.49 USD
|
+1.01%
|
|
-3.22%
|
-2.45%
|
|
01/06 |
Rothschild & Co Redburn Adjusts PT on Synopsys to $560 From $540, Maintains Buy Rating
|
MT
| |
28/05 |
Deutsche Bank Adjusts Synopsys Price Target to $590 From $580, Maintains Buy Rating
|
MT
| |
28/05 |
BNP Paribas Adjusts Synopsys Price Target to $450 From $425, Maintains Underperform Rating
|
MT
| |
28/05 |
Morgan Stanley Adjusts Price Target on Synopsys to $525 From $480, Maintains Equalweight Rating
|
MT
| |
28/05 |
Wells Fargo Adjusts Price Target on Synopsys to $535 From $505, Maintains Equalweight Rating
|
MT
| |
28/05 |
Piper Sandler Adjusts Price Target on Synopsys to $450 From $430, Maintains Neutral Rating
|
MT
| |
28/05 |
Baird Adjusts Price Target on Synopsys to $558 From $555, Maintains Neutral Rating
|
MT
| |
28/05 |
Stifel Adjusts Price Target on Synopsys to $600 From $550, Maintains Buy Rating
|
MT
| |
28/05 |
Citigroup Adjusts Price Target on Synopsys to $610 From $600, Maintains Buy Rating
|
MT
| |
28/05 |
HSBC Adjusts Price Target on Synopsys to $490 From $460, Maintains Hold Rating
|
MT
| |
27/05 |
Berenberg Raises Price Target on Synopsys to $633 From $540, Keeps Buy Rating
|
MT
| |
26/05 |
Rosenblatt Securities Adjusts Price Target on Synopsys to $575 From $530, Maintains Buy Rating
|
MT
| |
22/05 |
Baird Adjusts Price Target on Synopsys to $555 From $499, Maintains Neutral Rating
|
MT
| |
14/05 |
Wells Fargo Adjusts Price Target on Synopsys to $505 From $450, Maintains Equalweight Rating
|
MT
| |
13/05 |
Citigroup Adjusts Price Target on Synopsys to $600 From $580, Maintains Buy Rating
|
MT
| |
17/04 |
Baird Adjusts Synopsys Price Target to $499 From $555, Maintains Neutral Rating
|
MT
| |
27/02 |
Synopsys' Growth Outlook Softens as Core Business Slows, Morgan Stanley Says
|
MT
| |
27/02 |
Rothschild & Co Redburn Adjusts Price Target on Synopsys to $540 From $590, Maintains Buy Rating
|
MT
| |
27/02 |
Morgan Stanley Downgrades Synopsys to Equalweight From Overweight, Adjusts PT to $480 From $550
|
MT
| |
27/02 |
Griffin Securities Lowers Synopsys Price Target to $538 From $560
|
MT
| |
26/02 |
Synopsys is Fundamentally Immune to AI Disruption Fears, BofA Says
|
MT
| |
26/02 |
Synopsys is Fundamentally Immune to AI Disruption Fears, BofA Says
|
MT
| |
26/02 |
BofA Securities Adjusts Synopsys Price Target to $515 From $560, Maintains Buy Rating
|
MT
| |
26/02 |
HSBC Adjusts Synopsys PT to $460 From $455, Maintains Hold Rating
|
MT
| |
26/02 |
Piper Sandler Adjusts Synopsys PT to $430 From $520, Maintains Neutral Rating
|
MT
|
No results match your criteria
Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
|